Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | CASR | P41180 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | APEX1 | P27695 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6651861 | 0.84 | LOXL2 (0.60) | LOXL2HPGDHIF1ACYP1A2CYP2C9 | |
| SCHEMBL6651670 | 0.84 | LOXL2 (0.60) | LOXL2HPGDHIF1ACYP1A2CYP2C9 | |
| SCHEMBL6651863 | 0.84 | LOXL2 (0.60) | LOXL2HPGDHIF1ACYP1A2CYP2C9 | |
| SCHEMBL7363930 | 0.83 | LOXL2 (0.60) | LOXL2HPGDHIF1ACYP1A2CYP2C9 | |
| SCHEMBL5968633 | 0.82 | LOXL2 (0.67) | LOXL2HPGDHIF1ACYP1A2CYP2C9 | |
| SCHEMBL485998 | 0.82 | HPGD (0.64) | LOXL2HPGDHIF1ACYP1A2CYP2C9 | |
| SCHEMBL5968556 | 0.82 | LOXL2 (0.67) | LOXL2HPGDHIF1ACYP1A2CYP2C9 | |
| SCHEMBL12085830 | 0.82 | HPGD (0.64) | LOXL2HPGDHIF1ACYP1A2CYP2C9 | |
| SCHEMBL17947424 | 0.82 | HPGD (0.64) | LOXL2HPGDHIF1ACYP1A2CYP2C9 | |
| SCHEMBL5968526 | 0.82 | LOXL2 (0.67) | LOXL2HPGDHIF1ACYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100099721-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | PROBIODRUG AG (DE) | 2010-04-22 | — | — | US | disclosed |
| US-7667044-B2 | treating nervous system diorders such as Alzheimer's disease, Down Syndrome, Parkinson disease and Huntington chorea by administering inhibitors of prolyl endopeptidases | PROBIODRUG AG (DE) | 2010-02-23 | — | — | US | disclosed |
| EP-1824846-A2 | NOVEL COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | Probiodrug AG (DE) | 2007-08-29 | — | — | EP | disclosed |
| WO-2006058720-A2 | NOVEL COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | PROBIODRUG AG (DE) | 2006-06-08 | — | — | WO | disclosed |
| US-20060100253-A1 | Novel compounds for the treatment of neurological disorders | PROBIODRUG AG | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099721-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | PREP, BACE1, BCHE | LOXL2 2191/4885HPGD 672/4885HIF1A 1769/4885 |
| US-20060100253-A1 | Novel compounds for the treatment of neurological disorders | PREP, BACE1, BCHE | LOXL2 2557/4885HPGD 794/4885HIF1A 1944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.